Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is reportedly expecting 8-10 per cent growth in consolidated revenue in FY 17. The company expects its newly acquired branded drug business in Japan  to contribute to revenue  from second half of FY 17 and the guidance also takes into account continued impact of remediation measures at Halol plant and gains from sale of anti leukemia drug Gleevec for which it has 180 day exclusivity.

Moreover, the company will focus on building specialty business in the US and this may see a short term impact on its profitability. It will also increase spend on research and development to around 9 per cent of sales.

Sun Pharma which is country's largest drug maker posted net profit of Rs 1714 crore in Q4 FY 16, a growth of 92 per cent on a year-on-year basis on the back of strong sales growth in the US market.